Purified Anti-Lysophosphatidic Acid (LPA) monoclonal antibody.
Applications: ELISA, Immunohistochemistry, Immunocytochemistry
Product Background: Lysophosphatidic Acid (LPA) is a serum-derived phospholipid involved in diverse ceullular processes such as cell proliferation, chemotaxis, platelet aggregation, wound healing, angiogensis, tumor invasion, and smooth muscle contraction. Recent research indicates LPA may play a significant role in the pathophysiology of cancer and may be used as a biomarker for ovarian cancer. The Lysophosphatidic Acid Antibody (504B3) was originally developed and patented at Lpath Therapeutics.
Antibody is stable for up to 1 year at -20 °C. Antibody is stable for 60 days at 4°C. Avoid repeated freeze/thaw cycles.
1) J. Cheng, S. Sahani, T.J. Hausrat, et al. (2016) “Precise Somatotopic Thalamocortical Axon Guidance Depends on LPA-Mediated PRG-2/Radixin Signaling” Neuron, 92(1); 126-142. doi: doi:10.1016/j.neuron.2016.08.035
2) M. Balood, H. Zahednasab, et al. (2014) “Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis” Hum. Immunol. 75(5); 411-413, doi: 10.1016/j.humimm.2014.02.021
3) Y. Goldshmit, R. Matteo, et al. (2012) “Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes.” Am. J. Pathol. , 181(3): 978-992, doi: 10.1016/j.ajpath.2012.06.007
Bulk discounts available, please email firstname.lastname@example.org for information.